4,875 Shares in Illumina, Inc. $ILMN Bought by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,875 shares of the life sciences company’s stock, valued at approximately $857,000.

A number of other large investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Illumina during the second quarter valued at about $3,374,423,000. Plato Investment Management Ltd purchased a new position in shares of Illumina in the second quarter worth about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Illumina in the second quarter worth about $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina in the 2nd quarter valued at about $129,792,000. Finally, Impact Partnership Wealth LLC lifted its stake in shares of Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after acquiring an additional 7,780 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Insider Buying and Selling at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,799,688 shares of company stock valued at $379,517,231. 2.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Canaccord Genuity Group increased their price target on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Royal Bank Of Canada boosted their price objective on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Stifel Nicolaus upped their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Barclays increased their target price on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. Finally, Piper Sandler reissued an “overweight” rating and issued a $225.00 target price (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Illumina has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $215.59 on Monday. The firm has a market capitalization of $32.55 billion, a P/E ratio of 40.22, a P/E/G ratio of 3.03 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a 50 day moving average price of $194.05 and a 200-day moving average price of $155.87. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.